Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 1086-1092

  Delebecq, Thérèse Janecki ^a   Porte, Henri ^a   Zerimech, Farid ^a   Copin, Marie Christine ^a   Gouyer, Valérie ^a   Dacquembronne, Evelyne ^a   Balduyck, Malika ^a   Wurtz, Alain ^a   Huet, Guillemette ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN B; CATHEPSIN L; GELATINASE A; STROMELYSIN 3; UROKINASE;

ARTICLE; CANCER INVASION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LOCALIZATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; TUMOR VOLUME;

ADULT; AGED; BLOTTING, NORTHERN; CARCINOMA, NON-SMALL-CELL LUNG; CATHEPSIN B; CATHEPSINS; CYSTEINE ENDOPEPTIDASES; DATA INTERPRETATION, STATISTICAL; ENDOPEPTIDASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOASSAY; LUNG NEOPLASMS; LYMPH NODES; MALE; MATRIX METALLOPROTEINASE 11; MATRIX METALLOPROTEINASE 2; METALLOENDOPEPTIDASES; MIDDLE AGED; RNA, MESSENGER; URINARY PLASMINOGEN ACTIVATOR;

EID: 0034114776     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Duffy, M. J. Proteases as Prognostic Markers in Cancer. Clin. Cancer Res., 2: 613-618, 1996.
2. Woodhouse, E. C., Chuaqui, R. F., and Liotta, L. A. General mechanisms of metastasis. Cancer (Phila.), 80: 1529-1537, 1997.
3. Pedersen, H., Brünner, N., Francis, D., Osterlind, K., Ronne, E., Hoi Hansen, H., Dano, K., and Grondahl-Hansen, J. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res., 54: 4671-4675, 1994.
4. Pedersen, H., Grondahl-Hansen, J., Francis, D., Osterlind, K., Hoi Hansen, H., Dano, K., and Brunner, N. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res., 54: 120-123, 1994.
5. Bolon, I., Gouyer, V., Devouassoux, M., Vandenbunder, B., Wernert, N., Moro, D., Brambilla, C., and Brambilla, E. Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas. Am. J. Pathol., 147: 1298-1310, 1995.
6. Bolon, I., Devouassoux, M., Robert, C., Moro, D., Brambilla, C., and Brambilla, E. Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas. Am. J. Pathol., 150: 1619-1629, 1997.
7. Urbanski, S. J., Edwards, D. R., Maitland, A., Leco, K. J., Watson, A., and Kossalkowska, A. E. Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br. J. Cancer, 66: 1188-1194, 1992.
8. Kawano, N., Osawa, H., Ito, T., Nagashima, Y., Hirahara, F., Irayama, Y., Nakatani, Y., Kimura, S., Kitajim, H., Koshikawa, N., Miyazaki, K., and Kitamura, H. Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin and trypsin(ogen) in lung neoplasms: an immunohistochemical study. Hum. Pathol., 28: 613-622, 1997.
9. Anderson, I. C., Sugarbaker, D. J., Ganju, R. K., Tsarwhas, D. G., Richards, W. G., Sunday, M., Kobzik, L., and Shipp, M. A. Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts. Cancer Res., 55: 4120-4126, 1995.
10. Bolon, I., Brambilla, E., Vanderbunder, B., Robert, C., Lantuejoul, S., and Brambilla, C. Changes in the expression of matrix proteases and of the transcription factor C-Ets-1 during progression of precancerous bronchial lesions. Lab. Invest., 75: 1-13, 1996.
11. Werle, B., Ebert, W., Klein, W., and Spiess, E. Assessment of cathepsin L activity by use of the inhibitor CA-074 compared to cathepsin B activity in human lung tumor tissue. Biol. Chem. Hoppe-Seyler, 376: 157-164, 1995.
12. Ledakis, P., Tester, W. T., Rosenberg, N., Romero-Fischmann, D., Daskal, I., and Lak, T. T. Cathepsins D, B, and L in malignant human lung tissue. Clin. Cancer Res., 2: 561-568, 1996.
13. Inoue, T., Ishida, T., Sugio, K., and Sugimachi, K. Cathepsin B expression and laminin degradation as factors influencing prognosis of surgically treated patients with lung adenocarcinoma. Cancer Res., 54: 6133-6136, 1994.
14. Basset, P., Bellocq, J. P., Wolf, C., Stoll, I., Hutin, P., Limacher, J. M., Podhajcer, C. L., Chenard, M. P., Rio, M. C., and Chambon, P. A novel matrix metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature (Lond.), 348: 699-704, 1990.
15. Lemaire, R., Huet, G., Zerimech, F., Grard, G., Fontaine, C., Duquesnoy, B., and Flipo, R. M. Selective induction of the secretion of cathepsins B and L by cytokines in synovial fibroblast-like cells. Br. J. Rheumatol., 36: 735-743, 1997.
16. Lemaire, R., Flipo, R. M., Monté, D., Dupressoir, T., Duquesnoy, B., Cesbron, J. Y., Janin, A., Capron, A., and Lafyatis, R. Synovial fibroblast-like cells transfection with the SV40 large T antigen induces a transformed phenotype and permits transient tumor formation in immunodeficient mice. J. Rheumatol., 21: 1409-1419, 1994.
17. Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64: 327-336, 1991.
18. Foekens, J., Schmitt, M., Van Putten, W. L., Peters, A. H., Bontenbal, M., Janicke, F., and Klijn, J. G. M. Prognostic value of urokinase type plasminogen activator in 671 primary breast cancer patients. Cancer Res., 52; 6101-6105, 1992.
19. Janicke, F., Schmitt, M., Fache, L., Ulm, K., Harbeck, N., Höfler, H., and Graeff, H. Urokinase (u-PA), and its inhibitor PAI-1 are strong and independent prognostic factors in mode-negative breast cancer. Breast Cancer Res. Treat., 24: 195-208, 1993.
20. Fernö, M., Bendahl, PO., Borg, A., Brundell, J., Hirschberg, L., Olsson, H., and Killander, D. Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analyzed in steroid receptor cytosols with a luminometric immunoassay. Eur. J. Cancer, 32A: 793-801, 1996.
21. Peyrat, J. P., Vanlemmens, L., Fournier, J., Huet, G., Révillion, F., and Bonneterre, J. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers. Clin. Cancer Res., 4: 189-196, 1998.
22. Woessner, J. F. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J., 5: 2145-2154, 1991.
23. Pei, D., Majmudar, G., and Weiss, S. J. Hydrolytic inactivation of a breast carcinoma-cell-derived serpin by human stromelysin-3. J. Biol. Chem., 269: 25849-25855, 1994.
24. Crystal, R. G. α1-Antitrypsin deficiency, emphysema and liver disease: genetic basis and strategies for therapy. J. Clin. Int., 85: 1343-1352, 1990.
25. Dano, K., Andreasen, P. A., Grondahl-Hansen, J., Kristensen, P., Nielsen, L. S., and Skriver, L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res., 44: 139-266, 1985.
26. Mignatti, P., and Rifkin, D. B. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev., 73: 161-195, 1993.
27. Birkedal-Hansen, H. Proteolytic remodeling of extracellular matrix. Curr. Opin. Cell. Biol., 7: 728-735, 1995.
28. Engel, G., Heselmeyer, K., Aver, G., Backdahl, M., Eriksson, E., and Linder, S. Correlation between stromelysin-3 mRNA level and outcome of human breast cancer. Int. J. Cancer, 58: 830-835, 1994.
29. Muller, D., Wolf, C., Abecassis, J., Millon, R., Engelmann, A., Bronner, G., Rouyer, N., Rio, M. C., Eber, M., Methlin, G., Chambon, P., and Basset, P. Increased stromelysin-3 gene expression is associated with increased local invasiveness in head and neck squamous cell carcinomas. Cancer Res., 53: 165-169, 1993.
30. Newell, K. J., Witty, J. P., Rodgers, W. H., and Matrisian, L. M. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol. Carcinog, 10: 199-206, 1994.
31. Porte, H., Chastre, E., Prevot, S., Nordlinger, B., Empereur, S., Basset, P., Chambon, P., and Gespach, C. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int. J. Cancer, 64: 70-75, 1995.
32. Porte, H., Triboulet, J. P., Kotelevets, L., Carrat, F., Prévot, S., Nordlinger, B., DiGioia, Y., Wurtz, A., Comoglio, P., Gespach, C., and Chastre, E. Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: implications for prognosis. Clin. Cancer Res., 4: 1375-1382, 1998.
33. Ahmad, A., Hanby, A., Dublin, E., Poulsom, R., Smith, P., Barnes, D., Rubens, R., Anglard, P., and Hart, I. Stromelysin 3: an independent prognostic factor for relapse-free survival in node positive breast cancer and demonstration of novel breast carcinoma cell expression. Am. J. Pathol., 152: 721-728, 1998.